Tag: Sanofi
Sanofi: licensing agreement with Novavax for vaccine production
(AOF) – Sanofi (+0.67% to 93.80 euros) announced the conclusion of a co-exclusive licensing agreement with the American Novavax for the co-marketing of a Covid-19 vaccine and the development of…
Novavax jumps on COVID-19 licensing deal with Sanofi, lifts going-concern warning – 05/10/2024 at 1:25 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) (Updates) May 10 – ** Shares of vaccine manufacturer Novavax NVAX.O more than doubled premarket, rising 141% to $10.78 ** Company enters…
Pharmacy: Sanofi in turn turns the page on its anti-Covid vaccine
After the British AstraZeneca, it is the turn of Sanofi to give up its anti-Covid vaccine. The French group will now market that of its American competitor Novavax, which it…
High-priced licensing deal between Novavax and Sanofi sends shares soaring – 05/10/2024 at 1:38 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) (Recast of paragraphs 1 and 2, updating of share movements) Novavax NVAX.O entered into a licensing deal worth up to $1.2 billion…
Sanofi and Novavax announce alliance
The Sanofi and Novavax groups, former competitors in the manufacturing of vaccines against Covid-19, will form an alliance. French company Sanofi will market the anti-Covid vaccine from its American competitor…
Sanofi dividend is for May 15
By Alexandra Saintpierre Published on 04/30/2024 at 7:26 p.m. Photo credit © Sanofi (Boursier.com) — The Combined…
Sanofi: new positive data for Beyfortus – 05/02/2024 at 08:00
(CercleFinance.com) – Sanofi announces that its Beyfortus has reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared to…
Sanofi: encouraging results of Beyfortus against respiratory syncytial virus in infants
(AOF) – Beyfortus reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared to infants who had not been…
Sanofi: will present its advances at the ATS in San Diego – 04/26/2024 at 12:11 p.m.
(CercleFinance.com) – Sanofi announces that 25 abstracts on approved and experimental drugs will be presented at the international conference of the American Thoracic Society (ATS) which will be held from…
Sanofi: Rilzabrutinib Phase III Study Reaches Primary Endpoint
Published on 04/23/2024 at 7:05 a.m. April 23 (Reuters) – Sanofi SA: *PHASE III LUNA 3 STUDY OF RILZABRUTINIB FOR THE TREATMENT…
Sanofi: Phase III LUNA 3 study of rilzabrutinib for the treatment of immune thrombocytopenia met its primary endpoint
By Claude Leguilloux Published on 04/23/2024 at 7:42 a.m. Photo credit © Sanofi Corporate (Boursier.com) — Positive…
Sanofi contacts banks for spin-off of its consumer health business – 04/24/2024 at 10:48 a.m.
(AOF) – Sanofi has contacted banks to support it in the spin-off of its consumer health activities, Bloomberg announces. According to the media, this would be one of the biggest…